Septerna, Inc.
SEPNNasdaq
$33.40
↑ +5.8%Jul 17 close · end-of-day
Price
1Y↑ +178.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.5B
Enterprise Value
$1.1B
P/E
—
P/S
20.7
P/B
4.0
EV/EBITDA
—
PEG
—
FCF Yield
7.1%
Dividend Yield
—
Revenue (TTM)
$72.3M
Net Income (TTM)
-$36.0M
Free Cash Flow (TTM)
$106.9M
Gross Margin
—
Operating Margin
-77.1%
Net Margin
-49.9%
ROE
-9.5%
ROIC
-141.7%
Debt / Equity
—
Net Cash
$347.4M
Return 1Y
+164.7%
Company profile
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.
- CEO
- Jeffrey Finer
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- septerna.com
Management & directors
- Bhatt ElizabethPresident and COO
- Long Daniel D.SVP, Drug Discovery
- Shaikhly SamiraChief People Officer
- Klein UweSVP, Biological Sciences
Roles derived from SEC Form 4 filings.
Earnings
SEPN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$26.5M↑ +12011.0%
Diluted EPS-$0.19↓ -61.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $151,000.00 | $1.1M | $46.0M |
| Gross profit | — | — | — |
| Operating income | $2.1M | -$80.8M | -$68.3M |
| Net income | $4.2M | -$71.8M | -$48.9M |
| Diluted EPS | $0.29 | -$7.26 | -$1.10 |
| Operating cash flow | -$38.7M | -$67.5M | $110.2M |
| Free cash flow | -$41.6M | -$69.6M | $109.7M |
| Gross margin | — | — | — |
| Operating margin | 1374.2% | -7518.4% | -148.6% |
| Net margin | 2768.2% | -6678.9% | -106.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $370,000.00 | $176,000.00 | $212,000.00 | $219,000.00 | $119,000.00 | $21.5M | $24.1M | $26.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$18.1M | -$22.6M | -$24.7M | -$25.9M | -$29.0M | $2.6M | -$16.0M | -$13.3M |
| Net income | -$16.5M | -$20.5M | -$20.7M | -$21.5M | -$24.8M | $8.2M | -$10.7M | -$8.6M |
| Diluted EPS | -$7.03 | -$8.40 | $14.52 | -$0.49 | -$0.56 | $0.18 | -$0.23 | -$0.19 |
| Operating cash flow | -$13.0M | -$16.8M | -$21.0M | -$23.3M | -$20.3M | $168.8M | -$15.0M | -$25.6M |
| Free cash flow | -$13.1M | -$17.4M | -$21.6M | -$23.7M | -$20.3M | $168.8M | -$15.1M | -$26.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -4882.4% | -12812.5% | -11659.4% | -11831.1% | -24351.3% | 12.2% | -66.4% | -50.1% |
| Net margin | -4462.2% | -11660.8% | -9749.1% | -9806.4% | -20872.3% | 38.0% | -44.5% | -32.6% |
Company news
Jun 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Bhatt Elizabeth· President and COO | Sale | 4,000 | $33.99 | $135,974.00 | filing |
| 2026-07-15 | Bhatt Elizabeth· President and COO | Option exercise | 4,000 | $6.81 | $27,240.00 | filing |
| 2026-07-01 | Long Daniel D.· SVP, Drug Discovery | Sale | 2,100 | $34.10 | $71,602.44 | filing |
| 2026-07-01 | Long Daniel D.· SVP, Drug Discovery | Sale | 1,233 | $34.81 | $42,925.79 | filing |
| 2026-07-01 | Long Daniel D.· SVP, Drug Discovery | Option exercise | 3,333 | $2.76 | $9,199.08 | filing |
| 2026-06-29 | Shaikhly Samira· Chief People Officer | Sale | 2,178 | $35.18 | $76,622.04 | filing |
| 2026-06-29 | Shaikhly Samira· Chief People Officer | Option exercise | 2,178 | $6.81 | $14,832.18 | filing |
| 2026-06-22 | Long Daniel D.· SVP, Drug Discovery | Sale | 8,000 | $35.10 | $280,800.80 | filing |
| 2026-06-22 | Long Daniel D.· SVP, Drug Discovery | Sale | 7,000 | $35.97 | $251,780.90 | filing |
| 2026-06-22 | Long Daniel D.· SVP, Drug Discovery | Option exercise | 4,471 | $11.70 | $52,310.70 | filing |
| 2026-06-22 | Long Daniel D.· SVP, Drug Discovery | Option exercise | 10,529 | $2.76 | $29,060.04 | filing |
| 2026-06-12 | Shaikhly Samira· Chief People Officer | Sale | 6,250 | $35.08 | $219,224.38 | filing |
| 2026-06-12 | Shaikhly Samira· Chief People Officer | Option exercise | 6,250 | $11.70 | $73,125.00 | filing |
| 2026-06-01 | Shaikhly Samira· Chief People Officer | Sale | 2,889 | $29.66 | $85,696.12 | filing |
| 2026-06-01 | Shaikhly Samira· Chief People Officer | Sale | 1,700 | $27.78 | $47,231.27 | filing |
| 2026-06-01 | Shaikhly Samira· Chief People Officer | Sale | 1,346 | $28.79 | $38,755.11 | filing |
| 2026-06-01 | Shaikhly Samira· Chief People Officer | Option exercise | 4,355 | $1.55 | $6,750.25 | filing |
| 2026-06-01 | Shaikhly Samira· Chief People Officer | Option exercise | 943 | $2.76 | $2,602.68 | filing |
| 2026-06-01 | Shaikhly Samira· Chief People Officer | Option exercise | 637 | $2.76 | $1,758.12 | filing |
| 2026-05-26 | Shaikhly Samira· Chief People Officer | Sale | 11,798 | $30.06 | $354,656.14 | filing |
| 2026-05-26 | Shaikhly Samira· Chief People Officer | Option exercise | 11,798 | $6.81 | $80,344.38 | filing |
| 2026-04-15 | Bhatt Elizabeth· President and COO | Sale | 2,573 | $23.76 | $61,123.67 | filing |
| 2026-04-15 | Bhatt Elizabeth· President and COO | Sale | 1,101 | $25.24 | $27,788.58 | filing |
| 2026-04-15 | Bhatt Elizabeth· President and COO | Option exercise | 4,000 | $6.81 | $27,240.00 | filing |
| 2026-04-15 | Bhatt Elizabeth· President and COO | Sale | 326 | $25.86 | $8,431.11 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.